In Honor of International Rare Disease Day, Abeona Therapeutics (Nasdaq: ABEO) Set to Ring the Nasdaq Stock Market Closing Be...
February 27 2017 - 10:39AM
What: Abeona Therapeutics Inc.
(Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company
focused on developing therapies for life-threatening rare genetic
diseases, will visit the Nasdaq MarketSite in Times Square to raise
awareness for Rare Disease Day.
In honor of the occasion, Timothy J. Miller, Ph.D.,
President and Chief Executive Officer, will ring the
Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Tuesday, February 28, 2017 – 3:45 p.m. to
4:00 p.m. ET
Abeona Contact:Andre’a
Lucca212.786.6208alucca@abeonatherapeutics.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About AbeonaAbeona Therapeutics Inc. is a
clinical-stage biopharmaceutical company developing gene therapies
for life-threatening rare genetic diseases. Abeona's lead programs
include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU),
adeno-associated virus (AAV) based gene therapies for Sanfilippo
syndrome (MPS IIIA and IIIB, respectively). Abeona is also
developing EB-101 (gene-corrected skin grafts) for recessive
dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis
bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten
disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of
infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for
Fanconi anemia (FA) disorder and ABO-302 using a novel
CRISPR/Cas9-based gene editing approach to gene therapy for rare
blood diseases. In addition, Abeona has a plasma-based protein
therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor)
for inherited COPD, using its proprietary SDF™ (Salt Diafiltration)
ethanol-free process. For more information, visit
www.abeonatherapeutics.com.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables clients
to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 85 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
approximately 3,800 listed companies with a market value of $10.1
trillion and nearly 18,000 corporate clients. To learn more, visit:
business.nasdaq.com.
-NDAQA-
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024